Vagulienė, N. THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50%. PIA 2020, 4, 164-167.